Literature DB >> 33725228

Dexmedetomidine reversed hypoxia/reoxygenation injury-induced oxidative stress and endoplasmic reticulum stress-dependent apoptosis of cardiomyocytes via SIRT1/CHOP signaling pathway.

Ying Zhang1,2, Qihong Zhao3, Xiaohong Li2, Fuhai Ji4.   

Abstract

We aimed to investigate the protective role and mechanism of dexmedetomidine (DEX) on H9c2 cardiomyocytes after hypoxia/reoxygenation (H/R) injury. Six experimental groups were designed as follows: normal control group (group C), H/R group, H/R + DEX group, H/R + gastrodin group, H/R + Ex527 (SIRT1 inhibitor) group, and H/R + DEX + Ex527 group. Lactate dehydrogenase (LDH) activity and the levels of oxidative stress-related enzymes such as malondialdehyde (MDA), superoxide dismutase (SOD), catalase (CAT) and glutathione (GSH) were measured using corresponding commercial kits. Cell counting kit (CCK)-8 assay was used to detect cell survival rate while flow cytometry and caspase 3/7 activity were used to determine cell apoptosis, respectively. Western blot was used to detect the expression of silent information regulator 1 (SIRT1), C/EBP homologous protein (CHOP), cleaved-caspase-12/3 and pro-caspase-12/3 in each group. From our findings, when compared with H/R, H/R + Ex527 and H/R + DEX + Ex527 groups, DEX pretreatment of cells in H/R + DEX group significantly increased cell survival rate, and simultaneously reduced LDH activity, oxidative stress and the apoptosis rate of H9c2 cells with H/R injury. Moreover, DEX up-regulated SIRT1 expression level and down-regulated the levels of endoplasmic reticulum (ER) stress-related markers such as CHOP, cleaved-caspase-12 and cleaved-caspase-3, respectively. Ex527 could completely block DEX-induced upregulated expression of SIRT1, and partially blocked the DEX-induced downregulated expression levels of CHOP, cleaved-caspase-12 and cleaved-caspase-3. These results proved that DEX reversed H/R injury-induced oxidative stress and ER stress-dependent apoptosis of cardiomyocytes via SIRT1/CHOP signaling pathway.

Entities:  

Keywords:  DEXMEDETOMIDINE; Endoplasmic reticulum stress; H9c2 cardiomyocyte; Hypoxia/reoxygenation; SIRT1/CHOP signaling pathway

Mesh:

Substances:

Year:  2021        PMID: 33725228     DOI: 10.1007/s11010-021-04102-8

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  38 in total

Review 1.  Lead Optimization Resources in Drug Discovery for Diabetes.

Authors:  Pragya Tiwari; Ashish Katyal; Mohd F Khan; Ghulam Md Ashraf; Khurshid Ahmad
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2019       Impact factor: 2.895

2.  Oxymatrine Ameliorates Doxorubicin-Induced Cardiotoxicity in Rats.

Authors:  Yan-Yan Zhang; Minhan Yi; Yong-Pan Huang
Journal:  Cell Physiol Biochem       Date:  2017-09-21

3.  Quercetin attenuates oxidative stress-induced apoptosis via SIRT1/AMPK-mediated inhibition of ER stress in rat chondrocytes and prevents the progression of osteoarthritis in a rat model.

Authors:  Kai Feng; Zhaoxun Chen; Liu Pengcheng; Shuhong Zhang; Xiaoqing Wang
Journal:  J Cell Physiol       Date:  2019-03-10       Impact factor: 6.384

Review 4.  Sirtuins, Cell Senescence, and Vascular Aging.

Authors:  Yujiro Kida; Michael S Goligorsky
Journal:  Can J Cardiol       Date:  2015-12-08       Impact factor: 5.223

5.  Gastrodin protects rat cardiomyocytes H9c2 from hypoxia-induced injury by up-regulation of microRNA-21.

Authors:  Yu Xing; Ling Li
Journal:  Int J Biochem Cell Biol       Date:  2019-01-23       Impact factor: 5.085

6.  MicroRNA-223 protects neonatal rat cardiomyocytes and H9c2 cells from hypoxia-induced apoptosis and excessive autophagy via the Akt/mTOR pathway by targeting PARP-1.

Authors:  Xiaoxiao Liu; Yunfei Deng; Yifeng Xu; Wei Jin; Hongli Li
Journal:  J Mol Cell Cardiol       Date:  2018-03-31       Impact factor: 5.000

7.  Sirtuin1 activator SRT2183 suppresses glioma cell growth involving activation of endoplasmic reticulum stress pathway.

Authors:  Tian Ye; Liwen Wei; Ji Shi; Ke Jiang; Huizhe Xu; Lulu Hu; Lingkai Kong; Ye Zhang; Songshu Meng; Haozhe Piao
Journal:  BMC Cancer       Date:  2019-07-18       Impact factor: 4.430

8.  Experienced Use of Dexmedetomidine in the Intensive Care Unit: A Report of a Structured Consensus.

Authors:  Daniela Pasero; Fabio Sangalli; Massimo Baiocchi; Ilaria Blangetti; Sergio Cattaneo; Gianluca Paternoster; Marco Moltrasio; Elisabetta Auci; Patrizia Murrino; Francesco Forfori; Ester Forastiere; Maria Giovanna De Cristofaro; Giorgio Deste; Paolo Feltracco; Flavia Petrini; Luigi Tritapepe; Massimo Girardis
Journal:  Turk J Anaesthesiol Reanim       Date:  2017-06-01

9.  Effects of dexmedetomidine postconditioning on myocardial ischemia and the role of the PI3K/Akt-dependent signaling pathway in reperfusion injury.

Authors:  Xiang Yang Cheng; Xiao Yu Gu; Qin Gao; Qiao Feng Zong; Xiao Hong Li; Ye Zhang
Journal:  Mol Med Rep       Date:  2016-05-24       Impact factor: 2.952

10.  Dexmedetomidine in combination with morphine improves postoperative analgesia and sleep quality in elderly patients after open abdominal surgery: A pilot randomized control trial.

Authors:  Huai-Jin Li; Chun-Jing Li; Xiao-Na Wei; Jian Hu; Dong-Liang Mu; Dong-Xin Wang
Journal:  PLoS One       Date:  2018-08-14       Impact factor: 3.240

View more
  4 in total

1.  Dexmedetomidine alleviates inflammatory response and oxidative stress injury of vascular smooth muscle cell via α2AR/GSK-3β/MKP-1/NRF2 axis in intracranial aneurysm.

Authors:  Ze Zhang; Xiue Mu; Xiaohui Zhou
Journal:  BMC Pharmacol Toxicol       Date:  2022-10-23       Impact factor: 2.605

2.  Dexmedetomidine protects cardiomyocytes against hypoxia/reoxygenation injury via multiple mechanisms.

Authors:  Shunv Cai; Yixing Liu; Yun Cheng; Junbo Yuan; Jun Fang
Journal:  J Clin Lab Anal       Date:  2021-12-09       Impact factor: 3.124

3.  Dexmedetomidine prevents cardiomyocytes from hypoxia/reoxygenation injury via modulating tetmethylcytosine dioxygenase 1-mediated DNA demethylation of Sirtuin1.

Authors:  Li Wang; Shaowei Wang; Tong Jia; Xiaojia Sun; Zhen Xing; Hui Liu; Jie Yao; Yanlin Chen
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

Review 4.  Amelioration of myocardial ischemia/reperfusion injury in diabetes: A narrative review of the mechanisms and clinical applications of dexmedetomidine.

Authors:  Meng Sun; Rong Wang; Rui Xia; Zhengyuan Xia; Zhilin Wu; Tingting Wang
Journal:  Front Pharmacol       Date:  2022-08-31       Impact factor: 5.988

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.